Guangzhou Enkaisai Biotechnology

Enkacy Biotech is a clinical-stage biopharmaceutical company based in Guangzhou, China, focused on the development of innovative Natural Killer (NK) cell therapies. The company was founded by Academician Tian Zhigang, a pioneer in NK cell research, to translate decades of academic excellence into transformative cancer treatments. Enkacy utilizes a proprietary synthetic immunology platform to engineer logic-gated CAR-NK cells that can specifically target and eliminate tumor cells while resisting the immunosuppressive tumor microenvironment. Their lead programs include off-the-shelf NK cell products and CAR-NK therapies targeting both solid tumors and hematological malignancies. By leveraging the unique biology of NK cells, Enkacy aims to overcome the limitations of current T-cell based therapies, such as cytokine release syndrome and graft-versus-host disease.